Department of Gynaecology and Obstetrics, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China.
Front Immunol. 2023 Jan 11;13:1065379. doi: 10.3389/fimmu.2022.1065379. eCollection 2022.
Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, , and investigations are still warranted in the future.
宫颈癌是一个具有广泛临床重要性的公共卫生问题。多年来，切除修复交叉互补基因 1（ERCC1）被发现是宫颈癌有前途的生物标志物。目前，尚无相关综述文章对这些证据进行总结。在本综述中，纳入了 19 项符合条件的研究进行评估和数据提取。基于临床和实验研究的数据，ERCC1 在子宫颈癌的进展和放化疗的治疗反应中发挥关键作用。纳入的大多数研究（13/19，68%）表明，ERCC1 在早期和晚期宫颈癌中均发挥致癌作用。高表达 ERCC1 与患者生存率较差相关。ERCC1 多态性分析表明，ERCC1 可能是预测宫颈癌风险和治疗相关毒性的有用工具。实验研究表明，ERCC1 在宫颈癌中发挥的生物学效应可能是由其相关基因和受影响的信号通路介导的（即 XPF、TUBB3 和 ）。为了通过针对 ERCC1 来推动宫颈癌的临床应用，未来仍需要更多的临床、和 研究。
